El interés en corto de Cocrystal Pharma da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Cocrystal Pharma. Los datos de interés en corto se actualizan cada dos semanas.

Cocrystal Pharma (NASDAQ:COCP) Bolsa, Informe de interés en corto

Cocrystal Pharma

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

Cocrystal Pharma Inc

Helix Energy Solns Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLX#NYSE">HLX</a>) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.03 by 33.33 percent. This is a 166.67 percent increase over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $278.06 million which missed the analyst consensus estimate of $284.24 million by 2.17 percent. This is a 6.13 percent decrease over sales of $296.21 million the same period last year.

Earnings

Earnings Misses

News

Helix Energy Solns Gr Q1 EPS $0.02 Misses $0.03 Estimate, Sales $278.06M Miss $284.24M Estimate

Banning Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) chips won&#8217;t stop China&#8217;s artificial intelligence development, according to Bernstein analysts, who suggest the export restrictions could instead strengthen domestic competitors like Huawei Technologies.
What Happened: &#8220;Banning the H20 would make no sense as its performance is already well below Chinese alternatives; a ban would simply hand the Chinese AI market completely over to Huawei,&#8221; Bernstein analysts wrote Wednesday, <a href="https://www.businessinsider.com/nvidia-chip-export-bans-unlikely-hinder-china-ai-growth-2025-4">reported</a> Business Insider.
The President Donald Trump administration is expected to require licenses for exporting powerful AI semiconductors to China, effectively creating an export ban, <a href="https://www.benzinga.com/25/04/44835247/nvidias-reported-failure-to-inform-chinese-clients-on-new-chip-restrictions-could-give-huawei-a-strategic-edge?utm_source=chatgpt.com">Nvidia disclosed in a regulatory filing last week</a>. 
The company <a href="https://www.benzinga.com/25/04/44830406/nvidia-to-take-55-billion-hit-over-china-chip-export-restrictions-but-top-analyst-dan-ives-says-hes-not-overly-concerned-all-part-of-the-high-game-of-poker">anticipates a $5.5 billion charge</a> related to inventory and purchase commitments for its H20 chip in the first quarter ending April 27.
Chinese companies have been reducing dependence on Nvidia by training models on unrestricted edge devices like personal computers and connecting Huawei chips with Nvidia processors. According to Bernstein&#8217;s channel checks, &#8220;most companies are able to carry on without H20 chips.&#8221;
See Also:&nbsp;<a href="https://www.benzinga.com/news/earnings/25/04/44937440/tesla-q1-misses-estimates-as-tariff-pressures-weigh-on-outlook-lower-cost-evs-still-on-track" target="_blank" rel="noreferrer noopener">Tesla Q1 Misses Estimates As Tariff Pressures Weigh On Outlook, Lower-Cost EVs Still On Track</a>
Why It Matters: Huawei is reportedly preparing <a href="https://www.benzinga.com/25/02/43945751/huawei-boosts-ai-chip-production-despite-taiwan-semi-and-asml-ban-aims-to-challenge-nvidia-in-china?utm_source=chatgpt.com">mass shipments of its advanced 910C AI chip</a> as early as next month. The chip reportedly matches Nvidia&#8217;s H100 performance by integrating two 910B processors into a single package, according to Reuters.
Huawei has doubled the yield rate of its AI chips from about 20% a year ago to approximately 40% now, making its Ascend <a href="https://www.benzinga.com/25/02/43945751/huawei-boosts-ai-chip-production-despite-taiwan-semi-and-asml-ban-aims-to-challenge-nvidia-in-china?utm_source=chatgpt.com">chip production profitable for the first time</a>, the Financial Times reported. The company aims to reach the industry standard of 60% yield.
Chinese AI companies focused on foundation model subscriptions face the biggest challenge transitioning from Nvidia&#8217;s proprietary CUDA software. Bernstein noted one Chinese company required 200 engineers and six months to migrate to Huawei chips, achieving only 90% of previous performance.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/personal-finance/25/04/44889632/warren-buffetts-son-cashed-in-90k-instead-of-waiting-on-500-million-now-hes-using-buffett-bucks-to-build-his-own-dream-town-in-new-york" target="_blank" rel="noreferrer noopener">Warren Buffett&#8217;s Son Cashed In $90K Instead of Waiting on $500 Million — Now He&#8217;s Using ‘Buffett Bucks&#8217; to Build His Own Dream Town in New York</a></li>
</ul>
Image Via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Asia

Equities

Regulations

Global

Markets

Tech

NVDA

Nvidia Chip Ban Won't Stop China's AI Momentum, Say Analysts — Blocking H20 Would Hand Market To Huawei Amid Trump-Era Export Crackdown

Euronet Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EEFT#NASDAQ">EEFT</a>) reported quarterly earnings of $1.13 per share which beat the analyst consensus estimate of $1.05 by 7.62 percent. This is a 11.72 percent decrease over earnings of $1.28 per share from the same period last year. The company reported quarterly sales of $915.50 million which beat the analyst consensus estimate of $912.59 million by 0.32 percent. This is a 6.83 percent increase over sales of $857.00 million the same period last year.

Earnings Beats

EEFT

Euronet Worldwide Q1 Adj. EPS $1.13 Beats $1.05 Estimate, Sales $915.50M Beat $912.59M Estimate

In connection with the Secondary Offering, Sportradar agreed to concurrently purchase from the underwriters 3,000,000 Class A ordinary shares at a price per share equal to the price at which the underwriters purchase the shares from the Selling Shareholders in the Secondary Offering (the "Share Repurchase"), subject to the completion of the Secondary Offering. The Share Repurchase is part of the Company's existing $200 million share repurchase program and the Company intends to fund the Share Repurchase with cash on hand. The underwriters will not receive any underwriting fees for the shares being repurchased by the Company. The Secondary Offering is expected to close on April 25, 2025.

SRAD

Sportradar Prices Secondary Share Sale By Insiders At $22.50; Initiates Buyback Of 3M Shares Using Cash Reserves

Nokia lands strategic 5G RAN deal with T-Mobile US to enhance nationwide connectivity
<ul>
<li>Nokia boosts T-Mobile US's award-winning 5G network with network footprint expansion and site modernization.</li>
<li>Partnership brings enhanced 5G connectivity to additional T-Mobile subscribers across the country.</li>
<li>Nokia to supply equipment from industry-leading AirScale portfolio.</li>
</ul>

Nokia Secures Multi-Year 5G RAN Deal With T-Mobile US To Expand And Modernize Nation-Leading Network

ARBE

Arbe-Powered LRR615 Imaging Radar Debuts In China Via Hirain, Offering High Sensitivity And Low False Alarm Rate

On Wednesday, following Tesla Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) <a href="https://www.benzinga.com/news/earnings/25/04/44937440/tesla-q1-misses-estimates-as-tariff-pressures-weigh-on-outlook-lower-cost-evs-still-on-track">first-quarter earnings report</a>, longtime investor and Future Fund managing partner Gary Black voiced skepticism over the company's strategy to offer lower-priced EVs.
What Happened: In a post on X, formerly Twitter, Black expressed concern that these upcoming affordable models will simply be decontented versions of the existing Model 3 and Model Y, rather than entirely new vehicles that could expand Tesla's total addressable market (TAM).
Black stated that Tesla CFO Vaibhav Taneja said during the call that these vehicles would be "within the [existing] form factor," which reinforced his view that the models may not attract new buyers but instead cannibalize sales of more expensive versions.
Black also criticized Tesla CEO Elon Musk's <a href="https://www.benzinga.com/tech/25/04/44941657/elon-musk-equates-car-ownership-in-future-to-riding-a-horse-while-using-a-flip-phone-pierre-ferragu-says-teslas-iphone-moment-hinges-on-full-autonomy">analogy comparing Tesla's EV strategy</a> to Apple Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) disruption of Nokia Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>).
See Also:&nbsp;<a href="https://benzinga.com/markets/equities/25/04/44862552/ford-recalls-nearly-150000-vehicles-over-brake-and-powertrain-issues-nhtsa" target="_blank" rel="noreferrer noopener">Ford Recalls Nearly 150,000 Vehicles Over Brake And Powertrain Issues: NHTSA</a>
He argued that without truly new vehicle types, Tesla risks repeating its 2023-2024 pattern, when price cuts led to steep earnings estimate revisions with little volume growth.
A user on X said that cheap base models don't usually sell well because buyers prefer lightly used, better-equipped versions. The user predicted that the same might happen with Tesla, too.
In response, Black said analysts are currently expecting Tesla's sales declines to ease in the second quarter and even turn positive in the fourth quarter. However, if the affordable car flops or gets delayed, then Tesla's full-year 2025 deliveries could drop even more.
&#8220;Without the new more affordable car, TSLA [deliveries] would likely be revised to -5% to -8% YoY,&#8221; he stated.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">After reviewing yesterday's <a href="https://twitter.com/search?q=%24TSLA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TSLA</a> conference call transcript, we remain skeptical of TSLA's plans to introduce more affordable vehicles, which appear to be scaled down versions of existing M-Y and M-3 trims, rather than new form factors that allow <a href="https://twitter.com/search?q=%24TSLA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TSLA</a> to enter new segments… <a href="https://t.co/UnAgncb6yG">pic.twitter.com/UnAgncb6yG</a>
&mdash; Gary Black (@garyblack00) <a href="https://twitter.com/garyblack00/status/1915109198129451458?ref_src=twsrc%5Etfw">April 23, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It's Important: Tesla reported first-quarter revenue of $19.34 billion, marking a 9% decline from the same period last year and falling short of Wall Street's consensus estimate of $21.35 billion.
The EV giant noted that it will revisit its 2025 guidance during the second-quarter update. Despite the revenue miss, Tesla said it maintains sufficient liquidity to support both its current product roadmap and long-term plans for capacity expansion.
Tesla also reaffirmed that its more affordable vehicle models are still on schedule to enter production in the first half of 2025. Additionally, the company announced that volume production of its autonomous Robotaxi, dubbed the Cybercab, is slated to begin in 2026.
Price Action: Tesla shares climbed 5.37% on Wednesday, ending the session at $250.74. However, the stock is still down 33.89% year-to-date, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
According to Benzinga Edge Stock Rankings, Tesla holds a growth score of 67.63%. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Click here to see how it compares with other</a> companies in the sector.
Read Next:
<ul>
<li><a href="https://benzinga.com/25/04/44855242/charlie-munger-once-highlighted-how-warren-buffetts-lifelong-learning-made-berkshire-hathaways-success-possible-and-the-crucial-lesson-you-can-take-from-it" target="_blank" rel="noreferrer noopener">Charlie Munger Once Said Warren Buffett Is A ‘Learning Machine' And That's What Lies Beneath Berkshire Hathaway's Success From One Decade To Another</a></li>
</ul>
Photo Courtesy: Trygve Finkelsen on Shutterstock.com
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

AAPL

TSLA

Tesla's New Cheaper Cars Might Not Be The Game Changer Investors Hoped For, Warns Gary Black — Here's Why He Thinks They Could Hurt More Than Help

Autoliv Becomes Official Mobility Safety Partner Of Formula E To Promote Automotive And EV Safety Innovation

Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needs
Performance-based and program-based payments of in total US$ 75 m to Evotec

Evotec Deepens CELMoDs Alliance With Bristol Myers Squibb As Molecular Glue Degrader Pipeline Expands

Outlook 2025
In response to macro headwinds and uncertainty around trade tariffs, the Company is optimizing its 2025 spending plan and will employ its portfolio optionality. Mitigating actions around capex, portfolio, costs and other cash initiatives are expected to offset over €2 bln of negative scenario effects.&nbsp;
<ul>
<li>FY gross capex expected to be below €8.5 bln, down from an initial guidance of around €9 bln; net capex is seen below €6 bln from an initial guidance of 6.5-7 bln.</li>
<li>At a revised scenario of 65 $/bbl for the Brent price, 40 €/MWh for the TTF gas spot price, 3.5 $/bbl for the Standard Eni Refining margin and a EUR vs USD exchange rate of 1.1, the FY Group's CFFO before working capital adjustments is expected to be at €11 bln. This reflects a better outcome than the changes to the reference scenario imply.&nbsp;</li>
<li>Oil and gas production is still expected at 1.7 mln boe/d, assuming a FY Brent price of 65 $/bbl.&nbsp;</li>
<li>FY GGP proforma adjusted EBIT is confirmed at €0.8 bln with an upside to over €1 bln in the event of positive negotiation outcomes and supportive market scenario.&nbsp;</li>
<li>Enilive and Plenitude: o FY proforma adjusted EBITDA respectively of around €1 bln and above €1.1 bln; o End of year installed renewable capacity projected at more than 5.5 GW (Plenitude @100%); biorefinery capacity at 1.65 MTPA plus 1 MTPA under construction.</li>
</ul>

Guidance

Eni Outlook 2025: Plans To Offset Over €2B In Headwinds By Cutting 2025 Capex, Streamlining Portfolio, And Tightening Costs Amid Tariff Uncertainty

FY 2025 Guidance Unchanged The Company's guidance for FY 2025 under U.S. GAAP is unchanged. Guidance assumes no material change in exchange rates for key currencies compared with FY 2024 average rates, notably USD/GBP and USD/EUR. Guidance also assumes no material change to Medicaid eligibility policy and/or other changes to Federal funding levels due to executive actions. Guidance also does not include any potential impacts from tariffs imposed by the U.S. government or any retaliatory tariffs that may be imposed by other countries. FY 2025 Net Revenue (NR) $955m to $1,025m (-17% at the mid-point vs. FY 2024) SUBLOCADE NR $725m to $765m (-1% at the mid-point vs. FY 2024) OPVEE NR $10m to $15m SUBOXONE Film Market Share Accelerated NR decline in FY 2025 reflecting increased generic competitive activity and the potential impact from a fifth buprenorphine/ naloxone sublingual film generic in the U.S. market Non-GAAP Gross Margin Low to mid-80s % range Non-GAAP SG&amp;A ($525m) to ($535m) Non-GAAP R&amp;D ($85m) to ($90m) Non-GAAP Operating Income $185m to $225m

INDV

Indivior Reaffirms 2025 Guidance: Expects Net Revenue Of $995M-$1.025B Vs. $1.046B Est.; Sees Adj. Gross Profit Of $185M-$225M

Eni (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/E#NYSE">E</a>) reported quarterly earnings of $0.76 per share. This is a 27.21 percent decrease over earnings of $1.04 per share from the same period last year. The company reported $23.74 billion in sales this quarter. This is a 4.67 percent decrease over sales of $24.91 billion the same period last year.

Eni Q1 Adj. EPADS $0.76 Down From $1.04 YoY, Sales $23.74B Down From $24.91B YoY

A new biography on Elon Musk sheds light on the billionaire entrepreneur&#8217;s Icarus moment. Hubris Maximus, by Washington Post technology reporter Faiz Siddiqui, uncovers &#8220;The Shattering of Elon Musk&#8221; across three distinct periods in recent years.
What Happened: On Wednesday, Siddiqui offered a brief glimpse of his upcoming book on Musk, discussing his opinions on CNBC&#8217;s &#8220;Squawk Box.&#8221;
Siddiqui says that his book depicts the Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO in three distinct phases, starting with the controversial <a href="https://www.benzinga.com/news/23/01/30588579/elon-musk-tweets-funding-secured-in-2018-how-much-would-1-000-in-tesla-stock-be-worth-now">&#8220;funding secured&#8221; tweet</a> in 2018, which prompted a Securities and Exchange Commission investigation, followed by the COVID-19 era, and then the acquisition of Twitter, or as it&#8217;s now called, X.
See More: <a href="https://www.benzinga.com/personal-finance/25/04/44965461/elon-musks-ex-wife-jumped-into-a-random-thread-to-answer-what-it-takes-to-be-a-billionaire-her-message-the-world-doesnt-care-what-you-want">Elon Musk&#8217;s Ex-Wife Jumped Into a Random Thread To Answer What It Takes To Be a Billionaire — Her Message: The World Doesn&#8217;t Care What You Want</a>
The book describes a pattern that Siddiqui notices with Musk, which often involves a big event, such as the acquisition of Twitter, resulting in public backlash, followed by a quiet period, and then reinvention, with Musk moving on to something else.
According to Siddiqui, his book depicts several instances of individuals who &#8220;fiercely&#8221; and &#8220;devotedly&#8221; believed in Musk&#8217;s promises, and while they still support his goals, they were &#8220;disappointed in the man.&#8221;
Unlike Icarus, the author doesn&#8217;t believe that Musk has, or is going to, crash and burn. What&#8217;s &#8220;shattered&#8221; is essentially the &#8220;veneer on Elon,&#8221; Siddiqui says. &#8220;Elon was unimpeachably our Tony Stark,&#8221; he says, but he doesn&#8217;t think that&#8217;s true anymore, thanks to the tech mogul&#8217;s &#8220;Hubris,&#8221; or exaggerated pride. 
Why It Matters: Recently, Musk&#8217;s behavior and <a href="https://benzinga.com/general/health-care/25/01/42935746/is-elon-musks-mental-health-a-cause-for-concern-biographer-thinks-so">mental health issues</a> came under scrutiny when his biographer, Seth Abramson, voiced his fears.
Musk himself has <a href="https://www.benzinga.com/general/biotech/24/03/37797951/elon-musk-on-ketamine-and-investors-value-if-there-is-something-im-taking-i-should-keep-taking-it">acknowledged and defended</a> his use of prescription Ketamine to treat occasional depressive episodes, adding that the drug has been beneficial for investors in his companies.
Back in 2017, when asked if he was bipolar by a user on Twitter, Musk replied, &#8220;Yeah,&#8221; before adding, &#8220;Maybe not medically [though].&#8221; Around the same time, he tweeted about experiencing &#8220;greater highs, terrible lows, and unrelenting stress,&#8221; hinting at bipolar disorder.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The reality is great highs, terrible lows and unrelenting stress. Don&#39;t think people want to hear about the last two.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/891710778205626368?ref_src=twsrc%5Etfw">July 30, 2017</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Despite recent turbulence, many investors and analysts continue to express confidence in Elon Musk's leadership and long-term vision. 
On Wednesday, <a href="https://www.benzinga.com/25/04/44955303/tesla-stock-is-ripping-higher-wednesday-whats-driving-the-action">Tesla shares rallied</a> after Musk announced he would scale back his involvement in the Department of Government Efficiency starting in May, a market reaction that came in spite of the company's weak first-quarter results.
Analyst Dan Ives of Wedbush Securities <a href="https://www.benzinga.com/25/04/44945402/wedbushs-dan-ives-raises-teslas-price-target-to-350-as-musk-promises-to-significantly-reduce-doge-time">raised his target</a> for Tesla to $350, a 40% upside from current levels, merely on news of Musk&#8217;s return as a full-time CEO. This comes despite a range of challenges and headwinds now facing the EV giant. This &#8220;removes the black clouds over Tesla,&#8221; Ives said, as he will be &#8220;laser-focused&#8221; on Tesla again. 
Price Action: Tesla shares rallied 5.37% on Wednesday, following the company&#8217;s much-anticipated first quarter earnings, which was released on Tuesday.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="139" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24011533/Screenshot-2025-04-23-at-1.16.03-PM-1-1024x139.png" alt="" class="wp-image-885620" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24011533/Screenshot-2025-04-23-at-1.16.03-PM-1-1024x139.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24011533/Screenshot-2025-04-23-at-1.16.03-PM-1-300x41.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24011533/Screenshot-2025-04-23-at-1.16.03-PM-1-768x104.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24011533/Screenshot-2025-04-23-at-1.16.03-PM-1-1536x208.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24011533/Screenshot-2025-04-23-at-1.16.03-PM-1.png 1592w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
According to Benzinga Edge Stock Rankings, Tesla scores well across most metrics besides value. The price trend, however, remains unfavorable in the short, medium, and long term. For more such insights, sign up for <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Benzinga Edge</a> today!
Photo Courtesy: Shutterstock.com
Read More: <a href="https://www.benzinga.com/news/global/25/04/44967548/teslas-energy-division-shines-but-etf-risks-mount-amid-broader-challenges">Tesla&#8217;s Energy Division Shines, But ETF Risks Mount Amid Broader Challenges</a>

Elon Musk Was Our Tony Stark Until He Wasn't: Tesla CEO's Icarus Moment Chronicled In New Book

Indivior (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDV#NASDAQ">INDV</a>) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.24 by 70.83 percent. This is a 10.81 percent increase over earnings of $0.37 per share from the same period last year. The company reported quarterly sales of $266.00 million which beat the analyst consensus estimate of $262.35 million by 1.39 percent. This is a 6.34 percent decrease over sales of $284.00 million the same period last year.

Indivior Q1 Adj. EPS $0.41 Beats $0.24 Estimate, Sales $266.00M Beat $262.35M Estimate

The 3iQ Solana Staking ETF (SOLQ.U) has logged impressive gains since its debut a week ago, with Cathie Wood-led Ark Invest emerging as a major buyer.
What happened: The exchange-traded fund exposes investors to the price moves of Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), the sixth-largest cryptocurrency by market capitalization, while also generating passive rewards through staking.
The investment vehicle began trading on the Toronto Stock Exchange on April 16 and has since gained around 18% in value.&nbsp;
The ETF has <a href="https://www.benzinga.com/25/04/44880757/cathie-woods-pours-another-4-95-million-into-solana-staking-etf-dumps-bitcoin-etf-again">drawn the interest of Ark</a>, the asset management firm led by experienced investor Wood.
Ark Fintech Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#BATS">ARKF</a>) holds about 482,680 shares of the ETF, amounting to a stake worth $5.43 million, according to Ark's latest reported holdings.
See Also:<a href="https://www.benzinga.com/25/04/44621245/gold-backed-cryptos-match-yellow-metals-highs-following-trumps-liberation-day-shock"> </a><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44891685/gary-black-shares-polymarket-data-says-trump-tariffs-have-pushed-odds-of-2025-recession-to-57">Gary Black Shares Polymarket Data, Says Trump Tariffs Have Pushed Odds Of 2025 Recession To 57%</a>
Notably, the underlying asset SOL has also surged, gaining 13% in the last seven days.&nbsp;The Open Interest has surged 20% over the week to $5.63 billion, <a href="https://www.coinglass.com/BitcoinOpenInterest">according</a> to Coinglass.
While U.S. regulators&nbsp;<a href="https://www.benzinga.com/25/04/44850735/solana-price-falls-but-holds-key-support-as-canadian-etf-approval-institutional-buying-offer-support" target="_blank" rel="noreferrer noopener">have yet to approve any Solana ETFs</a>, asset managers including&nbsp;VanEck,&nbsp;Bitwise, and&nbsp;Grayscale&nbsp;have filed applications.&nbsp; The odds of their approval in 2025 <a href="https://polymarket.com/event/solana-etf-approved-in-2025">stood </a>at 73% on Polymarket, a cryptocurrency-based betting platform.
Price Action: At the time of writing, SOL was exchanging hands at $148.78, down 1.52% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. Year-to-date, the cryptocurrency has fallen 21.38%. Shares of the Solana Staking ETF closed 4.17% higher at $11.73 during Wednesday&#8217;s trading session.
Meanwhile, the ARKF ETF exhibited a high momentum score as of this writing. Visit&nbsp;<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound" target="_blank" rel="noreferrer noopener">Benzinga Edge Stock Rankings</a>&nbsp;to check out how other Ark ETFs perform on this metric.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="722" height="198" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24012604/Screenshot-2025-04-24-105547.png" alt="" class="wp-image-885630" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24012604/Screenshot-2025-04-24-105547.png 722w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24012604/Screenshot-2025-04-24-105547-300x82.png 300w" sizes="(max-width: 722px) 100vw, 722px" /></figure>
Photo: Lee Wa Da/Shutterstock
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44890965/shiba-inu-team-issues-major-anti-scam-alert-heres-what-you-need-to-know">Shiba Inu Team Issues Major Anti-Scam Alert: Here&#8217;s What You Need To Know</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$SOL

ARKF

Solana Staking ETF Surges 18% In Debut Week—Here's How Much Cathie Wood's Ark Invest Has Parked In It

<ul>
<li>Investment is in addition to the ongoing partnership as shared previously, including continuing the development of BCMA targeting ANKET&#xAE; program in autoimmune indications, and more</li>
</ul>

IPHA

Innate Pharma Confirms €15M Capital Increase Backed By Sanofi To Advance ANKET® Autoimmune Pipeline

Regarding the tariff situation, there could be some short-term disruption. We will continue to utilize the flexibility of our global manufacturing network to minimize impact of the evolving tariff landscape. Based on what we see today, we currently expect a EUR 20 to 30 million impact to our comparable operating profit in the second quarter from the current tariffs. Given the lack of visibility, we have not taken an assumption related to tariffs in the second half of 2025.

Nokia Stated That Tariffs May Cut Q2 Comparable Operating Profit By €20M–€30M; No Assumptions Made For H2 2025 Due To Ongoing Uncertainty

Only 15 percent of Americans, ages 18 to 29, think the nation is headed the right way, deepening what researchers call a generational crisis of confidence.
What Happened: The <a href="https://iop.harvard.edu/youth-poll/50th-edition-spring-2025">spring</a> Harvard Youth Poll of 2,096 respondents, aged between 18 and 29 years, found 51 percent believe the country is on the wrong track and 31 percent are unsure. Just 3 percent declined to answer. Trust in Washington is equally sparse, with only 19 percent saying the federal government "does the right thing" most of the time, while fewer than one in three trust Congress, the president, or the Supreme Court.
President Joe Biden still fares better than his successor on the question of who presided over sunnier times. 41 percent say the nation was better off under Biden, compared with 25 percent for former president-turned-incumbent Donald Trump.
Trump's approval rating among young people stands at 31 percent, virtually unchanged from the same point in his first term. Trust in congressional Democrats has tumbled to 23 percent, down from 42 percent in early 2019.
See also: <a href="https://www.benzinga.com/markets/equities/25/04/44970416/scott-bessents-china-de-escalation-scoop-delivered-to-wall-street-early-at-closed-door-event-2-2-trillion-in-gains-later-questions-arise-if-retail-investors-were">Scott Bessent&#8217;s China &#8216;De-Escalation&#8217; Scoop Delivered To Wall Street Early At Closed-Door Event — $2.2 Trillion In Gains Later Questions Arise If Retail Investors Were &#8216;Cheated&#8217;</a>
Pollsters tested nine items from Trump's 2025 agenda; none topped 35 percent support. The most popular, creating a <a href="https://www.benzinga.com/startups/24/11/42069236/trump-tasked-elon-musk-to-oversee-government-efficiency-heres-how-musk-has-streamlined-costs-at-his-own-companies">Department of Government Efficiency</a>, drew barely a third of young Americans. Tariffs, abolishing the Education Department, and pardons for Jan. 6 rioters each mustered backing from two in 10 or fewer.
Why It Matters: Data from the Harvard Youth Poll coincides with the release of a new Reuters/Ipsos survey, which finds approval of Trump's handling of the economy and inflation has <a href="https://www.benzinga.com/markets/25/04/44948841/trump-economic-approval-rating-drops-to-37-as-market-selloff-erodes-public-support-poll">slid to 37 percent</a>, down from 42 percent recorded just after his Jan. 20 inauguration. Together, the polls paint a picture of mounting public unease as Trump nears his 100-day mark.
Other gauges echo the turbulence. <a href="https://www.benzinga.com/news/25/04/44890428/trumps-gallup-approval-stands-at-45-topping-same-point-in-first-presidency-but-hes-down-16-in-economist-survey">Gallup</a> put Trump's overall approval at 45 percent in April — up from 41 percent at the same point in his first term — while an Economist/YouGov survey reported a 16-point plunge since January. An <a href="https://www.benzinga.com/news/global/25/03/44183107/trumps-approval-rating-48-voters-disapprove-of-handling-of-russia-ukraine-war-55-think-world-war-to-happen">Emerson College poll</a> in March showed a steadier 49 percent rating, even as opinions split over his handling of the Russia-Ukraine war. However, the latest Reuters/Ipsos figures suggest a sustained downward trend tied to economic anxieties and jittery financial markets.
Photo Courtesy: Joshua Sukoff on Shutterstock.com
Read next: <a href="https://www.benzinga.com/markets/equities/25/04/44970516/boeing-adjusts-strategy-amid-trump-tariff-fallout-ceo-kelly-ortberg-says-wont-build-aircraft-for-customers-who-will-not-take-them-as-china-halts-deliveries">Boeing Adjusts Strategy Amid Trump Tariff Fallout, CEO Kelly Ortberg Says Won&#8217;t &#8216;Build Aircraft For Customers Who Will Not Take Them&#8217; As China Halts Deliveries</a>

Government

Politics

Events

Trump Fails To Impress America's Young, Shows Poll As They Still Favor Biden — Only 15% Think US On Right Track

Guidance confirmed&nbsp;
<ul>
<li>In 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at CER5 . Sanofi confirms the expectation of a strong rebound in business EPS with growth at a low double-digit percentage at CER (before share buyback)6&nbsp;</li>
<li>Sanofi intends to complete a share buyback program in 2025 of €5 billion of which 72% was already repurchased</li>
</ul>

Sanofi Reaffirms 2025 Guidance: Sales To Grow Mid-To-High Single Digits (CER), Business EPS To Rise Low Double Digits (CER)

<ul>
<li>Dassault Systèmes' 3DEXPERIENCE platform will be used across Airbus, company-wide, for all future generations of civil and military aircraft and helicopters</li>
<li>More than 20,000 users from every business area and the value chain will collaborate and use Dassault Systèmes' virtual twins to improve efficiency, shorten development cycles and reduce costs</li>
<li>This is a key milestone in the digital transformation of Airbus' ways of working and the preparation of the next generation of aerospace products</li>
</ul>

DASTY

European Aeronautic Defence And Space Unsponsored

EADSY

Dassault Systèmes And Airbus Expand Strategic Partnership To Power Next-Gen Aircraft With 3DEXPERIENCE Platform

Press Releases

Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts

Cocrystal Pharma's Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins

Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections

Comments

Cocrystal Pharma

Interés en corto

Cocrystal Pharma (NASDAQ:COCP) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL